法律人 LawPlayer logo

資料由法律人 LawPlayer整理提供·EU law / curated by LawPlayer from EUR-Lex

Decision

Council Decision (EU) 2025/493 of 5 March 2025 on the position to be adopted on behalf of the European Union in the sixty-eighth session of the Commission on Narcotic Drugs on the scheduling of substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971

CELEX
Decision (EU) 2025/493
Date of document
Articles
4
Source
EUR-Lex
Article 1

The position to be taken on the Union’s behalf in the 68th session of the Commission on Narcotic Drugs, from 10 to 14 March 2025, when that body is called upon to adopt decisions on the addition of substances to the schedules to the United Nations Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and to the United Nations Convention on Psychotropic Substances of 1971, is set out in the Annex to this Decision.

Article 2

The position referred to in Article 1 shall be expressed by the Member States that are members of the Commission on Narcotic Drugs, acting jointly in the interest of the Union.

Article 3

This Decision is addressed to the Member States in accordance with the Treaties.

Schedules & Appendices

ANNEX

ANNEX

Position to be taken by the Member States which are members of the Commission on Narcotic Drugs, acting jointly, in the interest of the Union during the 68th session of the Commission on Narcotic Drugs planned to take place from 10 to 14 March 2025 regarding changes in the scope of control of substances:

(1)

N-pyrrolidino protonitazene (protonitazepyne) is to be included in Schedule I to the Convention on Narcotic Drugs (IUPAC name: 5-nitro-2-[(4-propoxyphenyl)methyl]-1-(2-pyrrolidin-1-ylethyl)benzimidazole).

(2)

N-pyrrolidino metonitazene (metonitazepyne) is to be included in Schedule I to the Convention on Narcotic Drugs (IUPAC name: 2-[(4-methoxyphenyl)methyl]-5-nitro-1-(2-pyrrolidin-1-ylethyl)-1H-benzoimidazole).

(3)

Etonitazepipne (N-Piperidinyl etonitazene) is to be included in Schedule I to the Convention on Narcotic Drugs (IUPAC name: 2-[(4-Ethoxyphenyl)methyl]-5-nitro-1-(2-piperidin-1-ylethyl)-1H-benzoimidazole).

(4)

N-desethyl-isotonitazene is to be included in Schedule I to the Convention on Narcotic Drugs (IUPAC name: N-ethyl-2-[2-[(4-isopropoxyphenyl)methyl]-5-nitro-benzimidazol-1-yl]ethanamine).

(5)

Hexahydrocannabinol is to be included in Schedule II to the Convention on Psychotropic Substances (IUPAC name: 6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol).

(6)

Carisoprodol is to be included in Schedule IV to the Convention on Psychotropic Substances (IUPAC name: (2RS)-2-[(carbamoyloxy)methyl]-2-methylpentyl (1-methylethyl)carbamate).

4 articles

Cite this act

Council Decision (EU) 2025/493 of 5 March 2025 on the position to be adopted on behalf of the European Union in the sixty-eighth session of the Commission on Narcotic Drugs on the scheduling of substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971 (EUR-Lex). Retrieved via LawPlayer, https://lawplayer.com/eu/act/32025D0493

© European Union, https://eur-lex.europa.eu, 1998-2026. Reuse authorised under Commission Decision 2011/833/EU, provided the source is acknowledged.

EU-EurLex-Reuse-2011-833

本頁資料來源:EUR-Lex·整理提供:法律人 LawPlayer· lawplayer.com